183 related articles for article (PubMed ID: 23617605)
21. Efficacy of different nitric oxide-based strategies in preventing experimental cerebral malaria by Plasmodium berghei ANKA.
Martins YC; Zanini GM; Frangos JA; Carvalho LJ
PLoS One; 2012; 7(2):e32048. PubMed ID: 22348145
[TBL] [Abstract][Full Text] [Related]
22. NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria.
Bertinaria M; Orjuela-Sanchez P; Marini E; Guglielmo S; Hofer A; Martins YC; Zanini GM; Frangos JA; Gasco A; Fruttero R; Carvalho LJ
J Med Chem; 2015 Oct; 58(19):7895-9. PubMed ID: 26367273
[TBL] [Abstract][Full Text] [Related]
23.
Elphinstone RE; Besla R; Shikatani EA; Lu Z; Hausladen A; Davies M; Robbins CS; Husain M; Stamler JS; Kain KC
Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28674030
[TBL] [Abstract][Full Text] [Related]
24. Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria.
Campos AC; Brant F; Miranda AS; Machado FS; Teixeira AL
Neuroscience; 2015 Mar; 289():166-80. PubMed ID: 25595981
[TBL] [Abstract][Full Text] [Related]
25. Treatment of malaria in a mouse model by intranasal drug administration.
Touitou E; Waknine JH; Godin B; Golenser J
Int J Parasitol; 2006 Dec; 36(14):1493-8. PubMed ID: 16942770
[TBL] [Abstract][Full Text] [Related]
26. Neuregulin-1 attenuates mortality associated with experimental cerebral malaria.
Solomon W; Wilson NO; Anderson L; Pitts S; Patrickson J; Liu M; Ford BD; Stiles JK
J Neuroinflammation; 2014 Jan; 11():9. PubMed ID: 24433482
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of proveblue (methylene blue) in an experimental cerebral malaria murine model.
Dormoi J; Briolant S; Desgrouas C; Pradines B
Antimicrob Agents Chemother; 2013 Jul; 57(7):3412-4. PubMed ID: 23612202
[TBL] [Abstract][Full Text] [Related]
28. Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice.
Recuenco FC; Takano R; Chiba S; Sugi T; Takemae H; Murakoshi F; Ishiwa A; Inomata A; Horimoto T; Kobayashi Y; Horiuchi N; Kato K
Malar J; 2014 Dec; 13():487. PubMed ID: 25495520
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.
DellaValle B; Hempel C; Staalsoe T; Johansen FF; Kurtzhals JA
Malar J; 2016 Aug; 15(1):427. PubMed ID: 27554094
[TBL] [Abstract][Full Text] [Related]
30. Transdermal delivery of artemisinins for treatment of pre-clinical cerebral malaria.
Zech J; Dzikowski R; Simantov K; Golenser J; Mäder K
Int J Parasitol Drugs Drug Resist; 2021 Aug; 16():148-154. PubMed ID: 34116478
[TBL] [Abstract][Full Text] [Related]
31. Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation.
Patil S; Joshi M; Pathak S; Sharma S; Patravale V
J Antimicrob Chemother; 2012 Nov; 67(11):2713-6. PubMed ID: 22899802
[TBL] [Abstract][Full Text] [Related]
32. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
33. Life-saving rectal artesunate for complicated malaria in children.
Pengsaa K; Sirivichayakul C; Na-Bangchang K; Thaiarporn I; Chaivisuth A; Wongsuwan A; Attanath P; Pojjaroen-Anant C; Wisetsing P; Chanthavanich P; Sabchareon A
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):597-601. PubMed ID: 16124423
[TBL] [Abstract][Full Text] [Related]
34. Xylopic acid-amodiaquine and xylopic acid-artesunate combinations are effective in managing malaria in Plasmodium berghei-infected mice.
Osei SA; Biney RP; Obese E; Agbenyeku MA; Attah IY; Ameyaw EO; Boampong JN
Malar J; 2021 Feb; 20(1):113. PubMed ID: 33632233
[TBL] [Abstract][Full Text] [Related]
35. Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine.
Adjei GO; Oduro-Boatey C; Rodrigues OP; Hoegberg LC; Alifrangis M; Kurtzhals JA; Goka BQ
Malar J; 2012 Dec; 11():420. PubMed ID: 23244570
[TBL] [Abstract][Full Text] [Related]
36. Controlled release of artemisone for the treatment of experimental cerebral malaria.
Golenser J; Buchholz V; Bagheri A; Nasereddin A; Dzikowski R; Guo J; Hunt NH; Eyal S; Vakruk N; Greiner A
Parasit Vectors; 2017 Mar; 10(1):117. PubMed ID: 28249591
[TBL] [Abstract][Full Text] [Related]
37. Perillyl alcohol exhibits in vitro inhibitory activity against Plasmodium falciparum and protects against experimental cerebral malaria.
Rodriguez AAM; Carvalho LJM; Kimura EA; Katzin AM
Int J Antimicrob Agents; 2018 Mar; 51(3):370-377. PubMed ID: 28843818
[TBL] [Abstract][Full Text] [Related]
38. RNA-seq-based transcriptome analysis of the anti-inflammatory effect of artesunate in the early treatment of the mouse cerebral malaria model.
Wang Q; Tang Y; Pan Z; Yuan Y; Zou Y; Zhang H; Guo X; Guo W; Huang X; Wu Z; Li C; Xu Q; Song J; Deng C
Mol Omics; 2022 Sep; 18(8):716-730. PubMed ID: 35960011
[TBL] [Abstract][Full Text] [Related]
39. Reduced cardiotoxicity and increased oral efficacy of artemether polymeric nanocapsules in Plasmodium berghei-infected mice.
Souza ACM; Mosqueira VCF; Silveira APA; Antunes LR; Richard S; Guimarães HN; Grabe-Guimarães A
Parasitology; 2018 Jul; 145(8):1075-1083. PubMed ID: 29223181
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.
Wilson NO; Solomon W; Anderson L; Patrickson J; Pitts S; Bond V; Liu M; Stiles JK
PLoS One; 2013; 8(4):e60898. PubMed ID: 23630573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
